Protagenic is a clinical-stage biopharmaceutical company developing PT00114, a synthetic brain signaling peptide designed to treat stress-related neuropsychiatric disorders including depression, anxiety, PTSD, and substance use disorder. PT00114 binds to Latrophilin-1 and Latrophilin-3 receptors to dampen overactive stress responses, a mechanism Protagenic argues differentiates the compound from treatments that directly block stress receptors. The company specifically targets patients who have failed or cannot tolerate existing therapies. Protagenic completed Phase I trials in 2025 and intends to begin Phase II trials in late 2026. Preclinical studies indicate PT00114 has a rapid onset, long-lasting effects, and a profile that avoids common side effects like sedation, weight gain, or dependence. As a pre-revenue company, Protagenic funds operations through equity financing and focuses spending on research and development. Protagenic maintains a minimal staff and outsources clinical trials, drug manufacturing, and other operations to third-party consultants and contract research organizations. The company holds an exclusive worldwide license for PT00114 from the University of Toronto and aims to eventually commercialize the drug through regulatory approval and potential partnerships or an acquisition by a larger pharmaceutical company. Protagenic is also in the early stages of developing follow-on compounds from the same peptide family.